Myoclonus

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 399-420

  Caviness, John N ^a   Truong, Daniel D ^b  

^a MAYO CLINIC   (United States)

^b Parkinson's and Movement Disorder Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BOOK; DISEASE MODEL; HUMAN; MYOCLONUS; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MYOCLONUS;

EID: 79954550904     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00031-8     Document Type: Book

References (200)

1. Andermann E., Andermann F., Carpenter S., et al. Action myoclonus-renal failure syndrome: a previously unrecognized neurological disorder unmasked by advances in nephrology. Adv Neurol 1986, 43:87-103.
2. Apartis E., Gaymard B., Verhaeghe S., et al. Predominant cortical dysfunction in Guadeloupean parkinsonism. Brain 2008, 131:2701-2709.
3. Armstrong M.B., Robertson P.L., Castle V. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol 2005, 33:365-367.
4. Ashby P., Chen R., Wennberg R., et al. Cortical reflex myoclonus studied with cortical electrodes. Clin Neurophysiol 1999, 110:1521-1530.
5. Asmus F., Gasser T. Inherited myoclonus-dystonia. Dystonia 4; Advances in Neurology 2004, Vol. 94:113-119. Lippincott Williams & Wilkins, Philadelphia.
6. Atakli D., Sozuer D., Atay T., et al. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 1998, 7:63-66.
7. Bachman D.S. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982, 39:49-52.
8. Badhwar A., Berkovic S.F., Dowling J., et al. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004, 127:2173-2182.
9. Bataller L., Graus F., Saiz A., et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001, 124:437-443.
10. Becker K., Goebel H.H., Svennerholm L., et al. Clinical, morphological, and biochemical investigations on a patient with an unusual form of neuronal ceroid-lipofuscinosis. Eur J Pediatr 1979, 132:197-206.
11. Berger J.R., Chumley W., Pittman T., et al. Persistent Coxsackie B encephalitis: Report of a case and review of the literature. J Neurovirol 2006, 12:511-516.
12. Bhatia K.P., Brown P., Gregory R., et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995, 118:1087-1093.
13. Bhatia K., Thompson P.D., Marsden D. Isolated postinfectious myoclonus. J Neurol Neurosurg Psychiatry 1992, 55:1089-1091.
14. Boccella P., Striano P., Zara F., et al. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters. Clin Neurol Neurosurg 2003, 106:55-59.
15. Boeve B.F. Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. Clin Sci (Lond) 2005, 109:343-354.
16. Boustany R.M., Alroy J., Kolodny E. Clinical classification of neuronal ceroid-lipofuscinosis subtypes. Am J Med Genet Suppl 1988, 5:47-58.
17. Bressman S., Fahn S. Essential myoclonus. Adv Neurol 1986, 43:287-294.
18. Brown P., Farmer S.F., Halliday D., et al. Coherent cortical and muscle discharge in cortical myoclonus. Brain 1999, 122:461-472.
19. Bruni J., Willmore L.J., Wilder B. Treatment of postanoxic intention myoclonus with valproic acid. Can J Neurol Sci 1979, 6:39-42.
20. Brunt E.R., van Weerden T.W., Pruim J., et al. Unique myoclonic pattern in corticobasal degeneration. Mov Disord 1995, 10:132-142.
21. Bugiani O., Murrell J.R., Giaccone G., et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999, 58:667-677.
22. Bureau M., Tassinari C.A. Epilepsy with myoclonic absences. Brain Dev 2005, 27:178-184.
23. Capovilla G., Rubboli G., Beccaria F., et al. A clinical spectrum of the myoclonic manifestations associated with typical absences in childhood absence epilepsy. A video-polygraphic study. Epileptic Disord 2001, 3:57-62.
24. Carella F., Ciano C., Panzica F., et al. Myoclonus in corticobasal degeneration. Mov Disord 1997, 12:598-603.
25. Carraz G., Fau R., Chateau R., et al. Communication concerning 1st clinical tests of the anticonvulsive activity of N-Dipropylacetic acid (sodium salt). Ann Med Psychol (Paris) 1964, 122:577-585.
26. Carroll W.M., Walsh P.J. Functional independence in post-anoxic myoclonus: contribution of L-5-HTP sodium valproate and clonazepam. Br Med J 1978, 2:1612.
27. Casado J.L., Gil-Peralta A., Graus F., et al. Anti-Ri antibodies associated with opsoclonus and progressive encephalomyelitis with rigidity. Neurology 1994, 44:1521-1522.
28. Caviness J. Clinical neurophysiology of myoclonus. Movement Disorders 2003, Vol. 1:521-548. Elsevier, Amsterdam.
29. Caviness J.N. Myoclonus and neurodegenerative disease - what's in a name?. Parkinsonism Relat Disord 2003, 9:185-192.
30. Caviness J.N., Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598-607.
31. Caviness J.N., Evidente V.G. Cortical myoclonus during lithium exposure. Arch Neurol 2003, 60:401-404.
32. Caviness J.N., Kurth M. Cortical myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 1997, 12:1046-1051.
33. Caviness J.N., Wszolek Z.K. Myoclonus in pallido-ponto-nigral degeneration. Adv Neurol 2002, 89:35-39.
34. Caviness J.N., Forsyth P.A., Layton D., et al. The movement disorder of adult opsoclonus. Mov Disord 1995, 10:22-27.
35. Caviness J.N., Adler C.H., Newman S., et al. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord 1998, 13:540-544.
36. Caviness J.N., Alving L.I., Maraganore D., et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999, 74:565-569.
37. Caviness J.N., Adler C.H., Beach T., et al. Myoclonus in Lewy body disorders. Adv Neurol 2002, 89:23-30.
38. Caviness J.N., Adler C.H., Beach T., et al. Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations. Mov Disord 2002, 17:657-662.
39. Caviness J.N., Adler C.H., Caselli R., et al. Electrophysiology of the myoclonus in dementia with Lewy bodies. Neurology 2003, 60:523-524.
40. Caviness J.N., Walker D.G., Beach T., et al. Parkinson's disease dementia mechanisms of cortical neuron dysfunction. Mov Disord 2009, 24:S294-S295.
41. Chadwick D., Reynolds E.H., Marsden C.D. Letter: Relief of action myoclonus by 5-hydroxytryptophan. Lancet 1974, 2:111-112.
42. Chadwick D., Hallett M., et al. Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. Adv Neurol 1986, 43:183-190.
43. Chi W.M., Chua K.S., Jenner P., et al. Phenytoin-induced asterixis - uncommon or under-diagnosed?. Brain Inj 2000, 14:847-850.
44. Cif L., Valente E.M., Hemm S., et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004, 19:724-727.
45. Corapcioglu F., Mutlu H., et al. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol 2008, 25:756-761.
46. Crest C., Dupont S., Kara B., et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004, 62:640-643.
47. Dalmau J., Graus F., Villarejo A., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127:1831-1844.
48. Delgado-Escueta A.V., Ganesh S., Yamakawa K., et al. Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 2001, 106:129-138.
49. Delgado-Escueta A.V., Medina M.T., Bai D., et al. Genetics of idiopathic myoclonic epilepsies: an overview. Adv Neurol 2002, 89:161-184.
50. Deuschl G., Mischke G., Schenck E., et al. Symptomatic and essential rhythmic palatal myoclonus. Brain 1990, 113:1645-1672.
51. Dhanuka A.K., Jain B.K., Daljit S., et al. Juvenile myoclonic epilepsy: a clinical and sleep EEG study. Seizure 2001, 10:374-378.
52. Digre K.B. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986, 43:1165-1175.
53. Dravet C., Bureau M., Oguni H., et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol 2005, 95:71-102.
54. Dropcho E.J., Kline L.B., Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993, 43:207-211.
55. Drury I., Blaivas M., Abou-Khalil B., et al. Biopsy results in a kindred with Lafora disease. Arch Neurol 1993, 50:102-105.
56. Ertle F., Behnisch W., Al Mulla N., et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008, 50:683-687.
57. Evidente V.G., Caviness J.N. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology 1999, 52:211-213.
58. Fahn S. Post-anoxic action myoclonus: improvement with valproic acid. N Engl J Med 1978, 299:313-314.
59. Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979, 26:49-84.
60. Fahn S. Posthypoxic action myoclonus: literature review update. Adv Neurol 1986, 43:157-169.
61. Ferlazzo E., Magaudda A., Striano P., et al. Long-term evolution of EEG in Unverricht-Lundborg disease. Epilepsy Res 2007, 73:219-227.
62. Fontoura P., Vale J., Lima C., et al. Progressive myoclonic ataxia and JC virus encephalitis in an AIDS patient. J Neurol Neurosurg Psychiatry 2002, 72:653-656.
63. Friedreich N. Neuropathologische Beobachtung beim Paramyoklonus Multiplex. Virch Arch Pathol Anat Physiol Klin Med 1881, 86:421-434.
64. Frucht S.J. The clinical challenge of posthypoxic myoclonus. Adv Neurol 2002, 89:85-88.
65. Frucht S.J., Louis E.D., Chuang C., et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57:1112-1114.
66. Genton P., Bureau M. Epilepsy with myoclonic absences. CNS Drugs 2006, 20:911-916.
67. Genton P., Gelisse P. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001, 57:1144-1145.
68. Genton P., Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000, 2:99-105.
69. Gobbi G., Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and gabaergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl) 2006, 185:255-262.
70. Goldings A.S., Stewart R.M. Organic lead encephalopathy: behavioral change and movement disorder following gasoline inhalation. J Clin Psychiatry 1982, 43:70-72.
71. Gordon M.F. Toxin and drug-induced myoclonus. Adv Neurol 2002, 89:49-76.
72. Gordon M.F., Abrams R.I., Rubin D., et al. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Mov Disord 1995, 10:220-222.
73. Guerrini R., Bonanni P., Parmeggiani L., et al. Pathophysiology of myoclonic epilepsies. Adv Neurol 2005, 95:23-46.
74. Guilleminault C., Tharp B.R., Cousin D. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J Neurol Sci 1973, 18:435-441.
75. Gwinn K.A., Caviness J.N. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord 1997, 12:438-442.
76. Hallett M. Early history of myoclonus. Adv Neurol 1986, 43:7-10.
77. Hallett M., Chadwick D., Adam J., et al. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry 1977, 40:253-264.
78. Henning S., Tings T., Schmidt H., et al. A case of cerebral Whipple's disease initially presenting with isolated focal myoclonus. Eur J Neurol 2006, 13:659-661.
79. Henry T.R. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003, 37:5-16.
80. Hersh B., Dalmau J., Dangond F., et al. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 1994, 44:1754-1755.
81. Hitomi T., Ikeda A., Matsumoto R., et al. Generators and temporal succession of giant somatosensory evoked potentials in cortical reflex myoclonus: epicortical recording from sensorimotor cortex. Clin Neurophysiol 2006, 117:1481-1486.
82. Hoizey G., Souchon P.F., Trenque T., et al. An unusual case of methyl bromide poisoning. J Toxicol Clin Toxicol 2002, 40:817-821.
83. Hustinx W.N., van de Laar R.T., van Huffelen A., et al. Systemic effects of inhalational methyl bromide poisoning: a study of nine cases occupationally exposed due to inadvertent spread during fumigation. Br J Ind Med 1993, 50:155-159.
84. Hwang E.C., Van Woert M.H. P, p'-DDT-induced neurotoxic syndrome: experimental myoclonus. Neurology 1978, 28:1020-1025.
85. Hwang E.C., Van Woert M.H. DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. Res Commun Chem Pathol Pharmacol 1979, 23:257-266.
86. Iivanainen M., Himberg J.J. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982, 39:236-238.
87. Jaksch M., Klopstock T., Kurlemann G., et al. Progressive myoclonus epilepsy and mitochondrial myopathy associated with mutations in the tRNA(Ser(UCN)) gene. Ann Neurol 1998, 44:635-640.
88. Jeavons P.M., Clark J.E., Maheshwari M. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate (epilim). Dev Med Child Neurol 1977, 19:9-25.
89. Jimenez-Jimenez F.J., Puertas I., de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 2004, 18:93-104.
90. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000, 37:103-110.
91. Johannessen C.U., Johannessen S.I. Valproate: past, present, and future. CNS Drug Rev 2003, 9:199-216.
92. Kakisaka Y., Haginoya K., Togashi N., et al. Neonatal-onset brainstem reticular reflex myoclonus following a prenatal brain insult: generalized myoclonic jerk and a brainstem lesion. Tohoku J Exp Med 2007, 211:303-308.
93. Kalviainen R., Khyuppenen J., Koskenkorva P., et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008, 49:549-556.
94. Kanai K., Hirose S., Oguni H., et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 2004, 63:329-334.
95. Kanthasamy A.G., Matsumoto R.R., Truong D. Animal models of myoclonus. Clin Neurosci 1995, 3:236-245.
96. Kanthasamy A.G., Nguyen B.Q., Truong D. Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization. Mov Disord 2000, 15:31-38.
97. Karacostas D., Doskas T., Artemis N., et al. Beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus. J Int Med Res 1999, 27:201-205.
98. Kaufman L.D., Kaufman M.A., Krupp L. Movement disorders in the eosinophilia-myalgia syndrome: tremor, myoclonus, and myokymia. J Rheumatol 1995, 22:157-160.
99. Kelly J.J., Sharbrough F.W., Daube J. A clinical and electrophysiological evaluation of myoclonus. Neurology 1981, 31:581-589.
100. Klawans H.L., Goetz c., et al. Levodopa-induced myoclonus. Arch Neurol 1975, 32:330-334.
101. Ko M.W., Dalmau J., Galetta S. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008, 28:58-68.
102. Koren G., Kennedy D. Safe use of valproic acid during pregnancy. Can Fam Physician 1999, 45:1451-1453.
103. Koren G., Nava-Ocampo A.A., Moretti M., et al. Major malformations with valproic acid. Can Fam Physician 2006, 52:441-442. 444, 447.
104. Koskiniemi M., Toivakka E., Donner M. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand 1974, 50:333-359.
105. Krauss G.L., Bergin A., Kramer R., et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001, 56:411-412.
106. Krueger B.R. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990, 65:999-1006.
107. Kurihara T., Landau W.M., Torack R. Progressive supranuclear palsy with action myoclonus, seizures. Neurology 1974, 24:219-223.
108. Kyllerman M., Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998, 29:109-114.
109. Lance J.W., Anthony M. Sodium valproate in the management of intractable epilepsy: comparison with clonazepam. Proc Aust Assoc Neurol 1975, 12:55-60.
110. Le Pajolec C., Marion M.H., Bobin S. Objective tinnitus and palatal myoclonus. A new therapeutic approach. Ann Otolaryngol Chir Cervicofac 1990, 107:363-365.
111. Lhermitte F., Peterfalvi M., Marteau R., et al. Pharmacological analysis of a case of postanoxic intention and action myoclonus. Rev Neurol (Paris) 1971, 124:21-31.
112. Liu X., Griffin I.C., Parkin S., et al. Involvement of the medial pallidum in focal myoclonic dystonia: A clinical and neurophysiological case study. Mov Disord 2002, 17:346-353.
113. Lugaresi E., Cirignotta F., Coccagna G., et al. Nocturnal myoclonus and restless legs syndrome. Adv Neurol 1986, 43:295-307.
114. Lu H.K., Lin T.Y., Hsia S., et al. Prognostic implications of myoclonic jerk in children with enterovirus infection. J Microbiol Immunol Infect 2004, 37:82-87.
115. Luque F.A., Furneaux H.M., Ferziger R., et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991, 29:241-251.
116. Magaudda A., Gelisse P., Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004, 45:678-681.
117. Mahloudji M., Pikielny R.T. Hereditary essential myoclonus. Brain 1967, 90:669-674.
118. Mahoney C.A., Arieff A.I. Uremic encephalopathies: clinical, biochemical, and experimental features. Am J Kidney Dis 1982, 2:324-336.
119. Marsden C., Fahn S. Problems in the dyskinesias. Movement Disorders 2 1987, 305-312. Butterworths, London. C.D. Marsden, S. Fahn (Eds.).
120. Marsden C.D., Hallett M., Fahn S. The nosology and pathophysiology of myoclonus. CD Marsden. Movement Disorders 1982, 196-248. Butterworths, London. S. Fahn (Ed.).
121. Marsden C.D., Harding A.E., Obeso J.A., et al. Progressive myoclonic ataxia (the Ramsay Hunt syndrome). Arch Neurol 1990, 47:1121-1125.
122. Marshall G.A., Doyle J.J. Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci 2006, 18:14-20.
123. Martins S., Matama T., Guimaraes L., et al. Portuguese families with dentatorubropallidoluysian atrophy (DRPLA) share a common haplotype of Asian origin. Eur J Hum Genet 2003, 11:808-811.
124. Matsumoto R.R., Hussong M.J., Truong D. Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus. Mov Disord 1995, 10:615-621.
125. Mellerio F., Levy-Alcover M.A. Myoclonus of toxic origin. Rev Electroencephalogr Neurophysiol Clin 1982, 12:210-218.
126. Meunier H., Carraz G., Neunier Y., et al. Propriétés pharmacodynamiques de l'acide n-dipropylacetique. Therapie 1963, 18:435-438.
127. Michelson D., Page S.W., Casey R., et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994, 21:2261-2265.
128. Mima T., Nagamine T., Ikeda A., et al. Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol 1998, 43:598-607.
129. Mirsattari S.M., Hammond R.R., Sharpe M., et al. Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology 2004, 62:1408-1410.
130. Misra U.K., Kalita J., Syam U., et al. Neurological manifestations of dengue virus infection. J Neurol Sci 2006, 244:117-122.
131. Mocellin R., Walterfang M., Velakoulis D. Hashimoto's encephalopathy: epidemiology, pathogenesis and management. CNS Drugs 2007, 21:799-811.
132. Munoz E., Mila M., Sanchez A., et al. Dentatorubropallidoluysian atrophy in a Spanish family: a clinical, radiological, pathological, and genetic study. J Neurol Neurosurg Psychiatry 1999, 67:811-814.
133. Murray K.O., Baraniuk S., Resnick M., et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004. Vector Borne Zoonotic Dis 2008, 8:167-174.
134. Nath A., Jankovic J., Pettigrew L. Movement disorders and AIDS. Neurology 1987, 37:37-41.
135. Obeso J.A. Therapy of myoclonus. Clin Neurosci 1995, 3:253-257.
136. Obeso J.A., Rothwell J.C., Marsden C.D. The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain 1985, 108:193-214.
137. Obeso J.A., Viteri C., Martinez Lage J., et al. Toxic myoclonus. Adv Neurol 1986, 43:225-230.
138. Obeso J.A., Artieda J., Quinn N., et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988, 11:529-536.
139. Obeso J.A., Artieda J., Rothwell J.C., et al. The treatment of severe action myoclonus. Brain 1989, 112:765-777.
140. Oguni H., Fukuyama Y., Tanaka T., et al. Myoclonic-astatic epilepsy of early childhood - clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. Brain Dev 2001, 23:757-764.
141. Oguni H., Hayashi K., Osawa M., et al. Severe myoclonic epilepsy in infancy: clinical analysis and relation to SCN1A mutations in a Japanese cohort. Adv Neurol 2005, 95:103-117.
142. Okuma Y., Mizuno Y. Myoclonic tremor in patients with parkinsonian-type multiple system atrophy. Mov Disord 2001, 16:378-379.
143. O'Rourke D., Flynn C., White M., et al. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Ir Med J 2007, 100:431-433.
144. Owens M.J., Nemeroff C.B. Pharmacology of valproate. Psychopharmacol Bull 2003, 37:17-24.
145. Penney S.E., Bruce I.A., Saeed S. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006, 253:857-860.
146. Peterson K., Rosenblum M.K., Kotanides H., et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
147. Pratt J.A., Rothwell J., Jenner P., et al. Myoclonus in the rat induced by p, p'-DDT and the role of altered monoamine function. Neuropharmacology 1985, 24:361-373.
148. Quinn N.P. Essential myoclonus and myoclonic dystonia. Mov Disord 1996, 11:119-124.
149. Quinn N.P., Rothwell J.C., Thompson P., et al. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol 1988, 50:391-401.
150. Reif A., Leonhard C., Mossner R., et al. Encephalopathy and myoclonus triggered by valproic acid. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1061-1063.
151. Rollinson R.D., Gilligan B.S. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate. Arch Neurol 1979, 36:44-45.
152. Roze E., Apartis E., Clot F., et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008, 70:1010-1016.
153. Saeed S.R., Brookes G.B. The use of clostridium botulinum toxin in palatal myoclonus. A preliminary report. J Laryngol Otol 1993, 107:208-210.
154. Salazar G., Valls-Sole J., Marti M.J., et al. Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord 2000, 15:77-83.
155. Sankar R., Wheless J.W., Dravet C., et al. Treatment of myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005, 95:289-298.
156. Scott B.L., Evans R.W., Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord 1996, 11:748-751.
157. Shakir R.A., Khan R.A., al-Zuhair A. Progressive myoclonic ataxia without ragged red fibres: Unverricht-Lundborg disease vs Ramsay Hunt syndrome. Acta Neurol Scand 1992, 86:470-473.
158. Shibasaki H. Electrophysiological studies of myoclonus. Muscle Nerve 2000, 23:321-335.
159. Shibasaki H., Neshige R. Photic cortical reflex myoclonus. Ann Neurol 1987, 22:252-257.
160. Shibasaki H., Motomura S., Yamashita Y., et al. Periodic synchronous discharge and myoclonus in Creutzfeldt-Jakob disease: diagnostic application of jerk-locked averaging method. Ann Neurol 1981, 9:150-156.
161. Stoupel N., Monseu G., Pardoe A., et al. Encephalitis with myoclonus in Whipple's disease. J Neurol Neurosurg Psychiatry 1969, 32:338-343.
162. Striano P., Manganelli F., Boccella P., et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005, 20:1610-1614.
163. Striano P., Zara F., Striano S. Autosomal dominant cortical tremor, myoclonus and epilepsy: many syndromes, one phenotype. Acta Neurol Scand 2005, 111:211-217.
164. Striano P., Tortora F., Evoli A., et al. Periodic myoclonus due to cytomegalovirus encephalitis in a patient with good syndrome. Arch Neurol 2007, 64:277-279.
165. Suyama N., Kobayashi S., Isino H., et al. Progressive supranuclear palsy with palatal myoclonus. Acta Neuropathol 1997, 94:290-293.
166. Tai K.K., Truong D.D. Post-hypoxic myoclonus induces Fos expression in the reticular thalamic nucleus and neurons in the brainstem. Brain Res 2005, 1059:122-128.
167. Tai K.K., Truong D.D. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm 2007, 114:1547-1551.
168. Tai K.K., Truong D.D. Ketogenic diet prevents seizure and reduces myoclonic jerks in rats with cardiac arrest-induced cerebral hypoxia. Neurosci Lett 2007, 425:34-38.
169. Tai K.K., Bhidayasiri R., Truong D. Post-hypoxic animal model of myoclonus. Parkinsonism Relat Disord 2007, 13:377-381.
170. Teepker M., Hamer H.M., Knake S., et al. Myoclonic encephalopathy caused by chronic bismuth abuse. Epileptic Disord 2002, 4:229-233.
171. Thomas J.E., Reagan T.J., Klass D. Epilepsia partialis continua. A review of 32 cases. Arch Neurol 1977, 34:266-275.
172. Thompson P.D., Shibasaki H. Myoclonus in corticobasal degeneration and other neurodegenerations. Adv Neurol 2000, 82:69-81.
173. Thompson P.D., Day B.L., Rothwell J., et al. The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. Brain 1994, 117:1197-1207.
174. Tison F., Arne P., Henry P. Myoclonus and adult coeliac disease. J Neurol 1989, 236:307-308.
175. Trottenberg T., Meissner W., Kabus C., et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001, 16:769-771.
176. Truong D.D., Garcia De Yebenes J., Pezzoli G., et al. Glycine involvement in DDT-induced myoclonus. Mov Disord 1988, 3:77-87.
177. Truong D.D., Galloway M.P., Pezzoli G., et al. Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain - possible mechanisms of milacemide antimyoclonic property in the p, p'-DDT-induced myoclonus. Pharmacol Biochem Behav 1989, 32:993-1001.
178. Truong D.D., Matsumoto R.R., Schwartz P., et al. Novel rat cardiac arrest model of posthypoxic myoclonus. Mov Disord 1994, 9:201-206.
179. Truong D.D., Kanthasamy A., Nguyen B., et al. Animal models of posthypoxic myoclonus: I. Development and validation. Mov Disord 2000, 15:26-30.
180. Truong D.D., Kirby M., Kanthasamy A., et al. Posthypoxic myoclonus animal models. Adv Neurol 2002, 89:295-306.
181. Tuzun E., Gurses C., Baykan B., et al. Lafora body-like inclusions in a case of progressive myoclonic ataxia associated with coeliac disease. Eur Neurol 2001, 46:157-158.
182. Uesaka Y., Terao Y., Ugawa Y., et al. Magnetoencephalographic analysis of cortical myoclonic jerks. Electroencephalogr Clin Neurophysiol 1996, 99:141-148.
183. Ugawa Y., Genba K., Shimpo T., et al. Somatosensory evoked potential recovery (SEP-R) in myoclonic patients. Electroencephalogr Clin Neurophysiol 1991, 80:21-25.
184. van Rootselaar A.F., van Schaik I.N., van den Maagdenberg A.M., et al. Familial cortical myoclonic tremor with epilepsy: a single syndromic classification for a group of pedigrees bearing common features. Mov Disord 2005, 20:665-673.
185. Van Woert M.H., Sethy V.H. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Neurology 1975, 25:135-140.
186. Varney S.M., Demetroulakos J.L., Fletcher M.H., et al. Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Otolaryngol Head Neck Surg 1996, 114:317-320.
187. Wakata N., Sugimoto H., Iguchi H., et al. A case of voluntary palatal myoclonus with ear click: relationship between palatal myoclonus and click. Eur Neurol 2002, 48:52-53.
188. Wallace S.J. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998, 29:147-154.
189. Wallace S.J. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001, 23:277-283.
190. Warner T.T., Williams L.D., Walker R., et al. A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol 1995, 37:452-459.
191. Westmoreland B. The EEG in cerebral inflammatory processes. Electroencephalography 1987, 264-266. Urban & Schwarzenberg, Baltimore. E. Niedermeyer, F.L. da Silva (Eds.).
192. Wierre L., Decaudin B., Barsumau J., et al. Dobutamine-induced myoclonia in severe renal failure. Nephrol Dial Transplant 2004, 19:1336-1337.
193. Wilkins D.E., Hallett M., Berardelli A., et al. Physiologic analysis of the myoclonus of Alzheimer's disease. Neurology 1984, 34:898-903.
194. Wolff M., Casse-Perrot C., Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 2006, 47:45-48.
195. Yiu V.W., Kovithavongs T., McGonigle L., et al. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001, 24:72-74.
196. Yoshimura I., Kaneko S., Yoshimura N., et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001, 46:283-287.
197. Young R.R., Shahani B.T. Asterixis: one type of negative myoclonus. Adv Neurol 1986, 43:137-156.
198. Zaccara G., Gangemi P.F., Cincotta M., et al. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008, 17:405-421.
199. Zhang C., Glenn D.G., Bell W., et al. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia 2005, 46:156-158.
200. Zifkin B., Andermann E., Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Curr Opin Neurol 2005, 18:147-153.